BME100 s2016:Group1 W1030AM L1

From OpenWetWare
Jump to navigationJump to search
BME 100 Spring 2016 Home
Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3
Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6
Course Logistics For Instructors
Wiki Editing Help


Niki Penrose
Cami Rowan
Eman Abu Alrahi
Richard Li
Kyler Blair
Carson Kennedy


Independent and Dependent Variables

Independent Variable - lipopolysaccharide dosage

Dependent Variable - inflammotin (inflammatory protein) levels in the blood; measured using ELISA

Experimental Design


There will be a control group given a placebo, or sugar pill while the second group is given the actual drug. The first group will be given 10 mg of the lipopolysaccharide. The following groups will receive dosages in decreasing amounts of 2mg (8mg, 6mg, 4mg) with the lowest dosage being 2mg before the control group who will be receiving 0mg in the placebo pill. The subjects will be randomly selected from the following age range and be of both genders and all races.

Researchers analyzing the data will not have the knowledge of the control group to reduce bias.


Since the pill was developed for the elderly, the age group for our test subjects will be in the age range of 65 years old to 75 years old.

Number of subjects per group

Each group will have 10 people making our experiment total be 60 people.

Subject Selection

Potential subjects will volunteer to participate in the experiment. They will be tested for relatively good health in order to participate. The population drawn from will be from the ages of 65-75 and the selection will be ultimately random.

Medical history will be noted down however the information will be withheld from researches analyzing the results.

Sources of Error and Bias


Demographics of individuals could result in different digestion of the protein and sway results. Each individual user is unlike that of lab rats with identical genetic makeup so individual results could be unreliable.

Individuals' diets or lifestyle changes could also sway the results through inconsistent variables.

Individuals selected may have prior medical history and actively volunteer for this study. The could bias the selection population towards those that have pre-existing conditions of lower levels of Inflammotin and result in error.

These errors will be reduced through using a completely randomized population with the medical background not revealed to researchers to prevent bias.

Potential clinical mistakes: There is always room for error in measurements, procedural errors could occur in dosages, the timing, etc. These should be eliminated through repetition and enforcing a more rigid timing structure.